U.S. CDC expects Omicron COVID boosters for kids by mid-October
Reuters
Published Sep 21, 2022 11:20AM ET
Updated Sep 21, 2022 02:51PM ET
(Reuters) - The U.S. Centers for Disease Control and Prevention expects COVID-19 vaccine boosters targeting circulating variants of the virus to be available for children aged 5-11 years by mid-October.
The CDC said in a document released on Tuesday that it expects to make a recommendation in early- to mid-October on the use of the new bivalent vaccines in the group, if they are authorized by the U.S. Food and Drug Administration (FDA). (https://
The vaccines, which target both the original version and the currently circulating variants of the virus, were rolled out for people 12 years or older earlier this month.
The CDC said it expects Pfizer-BioNTech's bivalent vaccine to be available for children aged 5-11 years, and Moderna (NASDAQ:MRNA)'s vaccine for those aged 6-17 years, pending FDA authorization.
The Pfizer (NYSE:PFE) vaccine is already authorized as a booster dose for children over 12 years of age, while Moderna's bivalent vaccine is authorized for adults.
The CDC expects pre-orders for the Pfizer shot to begin for the age group next week. The Moderna vaccine will have the same formulation for children and adults and will not require a separate pre-order period, the CDC said.
The United States government has ordered more than 170 million updated vaccine booster shots for this fall, and said on Tuesday it had sent out over 25 million doses.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.